

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Basha, et al.

SERIAL NO.: (not yet assigned)

FILED: September 19, 2003

FOR: SUBSTITUTED
DIAZABICYCLOALKANE DERIVATIVES

EXAMINER: (not yet assigned)

GROUP ART UNIT: (not yet assigned)


CASE NO.: 7128.US.O1

Express Mail Label No.: EV314259442US

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office to Addressee Service under 37 C.F.R. 1.10 addressed to:

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Date of Deposit: September 19, 2003

 9/19/03
Jenny Rizzotto Date

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, Applicants bring to the attention of the Examiner the documents listed on the attached Form PTO-1449. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

23492

ABBOTT LABORATORIES
Telephone: (847) 937-8272
Facsimile: (847) 938-2623

Respectfully submitted,
Basha, et al.


Rortia Chen
Registration No. 44,075
Attorney for Applicants

DATE: September 19, 2003

SHEET 1 of 2

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	ATTY. DOCKET NO. 7128.US.O1	SERIAL NO. (not yet assigned)
	APPLICANT(S) Basha, et al.	
	FILING DATE September 19, 2003	GROUP (not yet assigned)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	2002/0013309		Miller et al.	514	214.03	05/24/2001
	A2	2002/0019388		Schrimpf et al.	514	213.01	04/12/2001

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
	B1	00/34284	✓ 15.06.2000	WO			
	B2	00/44755	✓ 03.08.2000	WO			
	B3	00/71534	✓ 30.11.2000	WO			
	B4	01/44243	✓ 21.06.2001	WO			
	B5	01/81347	✓ 01.11.2001	WO			
	B6	01/90109	✓ 29.11.2001	WO			
	B7	02/04446	✓ 17.01.2002	WO			
	B8	02/44183	✓ 06.06.2002	WO			
	B9	03/044020	✓ 30.05.2003	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Adler et al, "Schizophrenia, sensory gating, and nicotinic receptors," Schizophrenia Bulletin 24(2):189-202 (1998)	✓
C2	Cordero-Erausquin et al., "Tonic nicotinic modulation of serotonergic transmission in the spinal cord," PNAS 98(5):2803-2807 (2001)	✓
C3	Friedman et al., "A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia," Biol. Psychiatry 51:349-357 (2002)	✓
C4	Heesch et al., "Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis," Nature Medicine 7(7):833-839 (2001)	✓
C5	Heesch et al., "A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors," Journal of Clinical Investigation 110(4):527-536 (2002)	✓

C6	Jonnala et al., "Relationship between the increased cell surface $\alpha 7$ nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists," Journal of Neuroscience Research 66:565-572 (2001)	✓
C7	Kihara et al., " $\alpha 7$ Nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A β -amyloid-induced neurotoxicity," Journal of Biological Chemistry 276(17):13541-13546 (2001)	✓
C8	Leonard et al., "Smoking and schizophrenia: abnormal nicotinic receptor expression," European Journal of Pharmacology 393:237-242 (2000)	✓
C9	Levin, "Nicotinic receptor subtypes and cognitive function," J. Neurobiol. 53:633-640 (2002)	✓
C10	Liu et al., " β -Amyloid peptide blocks the response of $\alpha 7$ -containing nicotinic receptors on hippocampal neurons," PNAS 98(8):4734-4739 (2001)	✓
C11	Rowley et al., "Current and novel approaches to the drug treatment of schizophrenia," Journal of Medicinal Chemistry 44(4):477-501 (2001)	✓
C12	Shimohama et al., "Nicotinic $\alpha 7$ receptors protect against glutamate neurotoxicity and neuronal ischemic damage," Brain Research 779:359-363 (1998)	✓
C13	Son et al., "Evidence suggesting that the mouse sperm acrosome reaction initiated by the zona pellucida involves an $\alpha 7$ nicotinic acetylcholine receptor," Biology of Reproduction 68:1348-1353 (2003)	✓
C14	Stevens et al., "Selective $\alpha 7$ -nicotinic agonists normalize inhibition of auditory response in DBA mice," Psychopharmacology 136:320-327 (1998)	✓
C15	Torii et al., "A versatile cycloaddition for the generation of pyrrolidine derivatives via C-N-C 1,3-dipoles," Chemistry Letters 747-748 (1996)	✓
C16	Wang et al., "Nicotinic acetylcholine receptor $\alpha 7$ subunit is an essential regulator of inflammation," Nature 421:384-388 (2003)	✓

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)